.
For economic and ethical reasons, identification of the optimal treatment for individual patients is a pressing concern that is particularly challenging, owing to the heterogeneity of OA and the very large number of those affected. The goal of pairing patients with the most appropriate therapies will be achieved, in part, by the identification and characterization of subsets of disease.
Macrophage-associated inflammation has been shown in vivo to be a prevalent phenomenon in radiographic OA, although the exact pathogenesis is still unclear 2 . Inflammation is thought to promote disease symptomatology and exacerbate disease progression in OA. In this Opinion article, we discuss the inflammatory processes involved in OA, along with findings related to a potential role of lipopoly saccharide in the pathogenesis of chronic subacute inflammation in OA. fibronectin 9 , hyaluronan 10, 11 , aggrecan 12 and others 13, 14 ), bacterial lipopeptides and lipopolysac charide. Relative to unaffected individuals, expression of TLRs is increased in OA, and this activation leads to elevated levels of nuclear factor κB (NFκB) and sCD14 (REF. 15 ). Elevated NFκB can induce activated joint cells to produce catabolic cytokines and chemokines, such as TNF, IL-1β, IL-6, receptor activator of NFκB ligand (RANKL) and IL-8, which in turn can increase the production of matrix metalloproteinases (MMPs), decrease collagen and proteoglycan synthesis and further augment NFκB activation 16 .
Responses to TLR2 and TLR4 ligands in fibroblast-like synoviocytes from patients with early OA are dependent on sCD14 (REF. 15 ). The level of sCD14 in synovial fluid from patients with OA correlates with the abundance of activated macrophages in knees affected by OA, and with the severity and progression of knee OA 6 . These results suggest that sCD14 shed from activated macrophages is a marker of activation of the innate immune system that has a pathogenic role in OA.
Chondrocytes contribute to the inflammatory process in OA through upregulation of the expression of TLR2 and TLR4, directly or indirectly activating MMPs such as MMP-1 and MMP-13 (REFS 17, 18) , which contribute to cartilage degeneration 19 . The alarmins S100A8 and S100A9 (Ca 2+ -binding proteins found in high amounts in the synovial fluids of patients with OA) have TLR4-dependent catabolic effects in OA-associated human chondrocytes 17, 20, 21 . Lipopolysaccharide can activate chondrocytes to induce production of complement C1r subcomponent, complement C3, complement factor B, mimecan (osteoglycin) and pentraxin-related protein PTX3, leading to activation of the complement cascade and generation of active complement proteins 22 , which can bind to receptors or deposit on cells of the synovium, leading to increased cytokine production. These results suggest that the innate inflammatory response induced by chondrocytes upon TLR4 activation not only induces the progression of OA, but also upregulates proinflammatory cytokines, exacerbating the existing low-grade inflammation and producing a recalcitrant, 'chronic' disease state 4 .
OA and low-grade inflammation
The concept of OA as a noninflammatory condition is slowly being supplanted by one in which low-grade inflammation (often subclinical) is not only prevalent in, but is also predictive of, articular chondropathy 3 . The existence of this kind of low-grade inflammation in patients with OA is widespread, both locally and, when joint disease is generalized, systemically 2 . The initiation and perpetuation of OA is intricately associated with activation of the innate immune system 4 involving the macrophage-associated inflammatory response 5 , activation of Toll-like receptor (TLR) pathways 4 , increases in levels of soluble CD14 (sCD14, a TLR co-receptor protein shed from activated proinflammatory macrophages) 6 and soluble CD163 (a scavenger receptor for the haemoglobin-haptoglobin complex) 6 , complement activation 7 and activation of the coagulation pathway (an intrinsic effector of innate immunity) 8 . TLRs are a group of membrane-associated pattern-recognition receptors that recognize fragments of the cartilage extracellular matrix (including 
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Abstract | The nature of the gastrointestinal microbiome determines the reservoir of lipopolysaccharide, which can migrate from the gut into the circulation, where it contributes to low-grade inflammation. Osteoarthritis (OA) is a low-grade inflammatory condition, and the elevation of levels of lipopolysaccharide in association with obesity and metabolic syndrome could contribute to OA. A 'twohit' model of OA susceptibility and potentiation suggests that lipopolysaccharide primes the proinflammatory innate immune response via Toll-like receptor 4 and that progression to a full-blown inflammatory response and structural damage of the joint results from coexisting complementary mechanisms, such as inflammasome activation or assembly by damage-associated molecular patterns in the form of fragmented cartilage-matrix molecules. Lipopolysaccharide could be considered a major hidden risk factor that provides a unifying mechanism to explain the association between obesity, metabolic syndrome and OA. 24 . Recurrent exposure to low-dose lipopolysaccharide increases mortality and induces cardiac fibrosis in mice 25 . Because of its pathophysiological properties, exogenous lipopolysaccharide has long been utilized in conjunction with collagen to induce arthritis in experimental animal models 24, 26 . The Gram-negative flora of the terminal ileum and large intestine constitute a large reservoir of lipopolysaccharide 27 . Absorption of lipopolysaccharide from the gut and transport to the portal vein is a normal physiological process 27 . Low-grade inflammation can result from intestinal absorption of lipopolysaccharide [28] [29] [30] . Although in humans lipopolysaccharide is normally associated with bacterial sepsis, shock and a high risk of mortality, low levels of lipopolysaccharide can be detected in the systemic circulation without acute illness 31 , suggesting an intriguing aetiology for the low-grade inflammation associated with many chronic diseases including rheumatoid arthritis (RA) 32 , inflammatory bowel disease 33 , type 1 diabetes mellitus 34 , atopy 35 and obesity 36 . As little as a single injection of a very low or moderate dose of lipopolysaccharide (0.6-3 ng/kg) in a healthy individual can induce immediate adipose tissue inflammation and systemic insulin resistance 37 . In RA, stimulation of the innate immune system, in part through the Systemic concentrations Systemic levels of lipopolysaccharide are elevated by several mechanisms in individuals with obesity 50, 51 (FIG. 2) . These mechanisms include impairment of clearance in the liver, alterations in the gut microbiota, permeability, motility and enzyme levels, and serum levels of HDL cholesterol.
Impaired clearance
The principal clearance site for both septic and physiological levels of lipopolysac charide is the liver. The Kupffer cells in the liver are the first line of defence against gut-derived toxins, preventing their entry into the systemic circulation. Impairment of this clearance and detoxification mechanism has been associated with liver diseases 27, 30 . One common form of liver dysfunction associated with the presence of systemic lipopolysaccharide is nonalcoholic fatty-liver disease (NAFLD); the prevalence of NAFLD is astonishingly high in the general population (20-30%) and in individuals with obesity (75-100%) 52 . NAFLD impairs the ability of the liver to clear systemic lipopolysaccharide 27, 30 . Importantly, high fat intake also leads to acute postprandial exposure to circulating lipopolysaccharide 53 , which can be attributed to the facilitation of the transport of bacterial lipopolysac charide from the intestine to the circulation by chylomicrons that are enriched in high-fat diets. In addition, intestinal insults such as inflammatory bowel disease that result in increased intestinal permeability can contribute to elevation of circulating lipopolysaccharide 54 .
Altered gut microbiota
A high-fat diet changes the composition of the murine gut microbiota, resulting in reductions in the levels of some Gram-positive and Gram-negative species, but not in overall numbers of bacteria 45 . Notably, compared with a normal diet, a high-fat diet significantly reduces numbers of the Gram-positive Bifidobacterium spp. that have been associated with reductions in intestinal lipopolysaccharide levels 55 . Modification of the composition of the murine gut microbiota by the dietary addition of nondigestible carbohydrates, such as prebiotics, improves gut-barrier integrity, reduces metabolic endotoxaemia and lowers inflammation, compared with supplementation with nonprebiotics, or no carbohydrate addition [56] [57] [58] . Introduction of prebiotic fibre to a high-fat diet specifically increases bifidobacterial numbers and reduces plasma lipopolysaccharide levels, compared with an unsupplemented high-fat diet 57 . microbiome, has been postulated to be an early event in disease causation 38 . Although a role for the microbiome has also been suggested for OA 39 , lipopoly saccharide and the microbiome are currently unexplored factors in the pathogenesis of this disease.
Intriguingly, many of the mechanisms now identified as having roles in the pathogenesis of OA overlap with the immune-activating functions of lipopolysaccharide 40 (FIG. 1) . These mechanisms include activation of the innate immune response through TLR4 and its coreceptor MD-2, which associates noncovalently with TLR4 on the cell surface and confers responsiveness to lipopolysaccharide 41, 42 , and also enhanced phagocytosis and cytotoxicity of macrophages 2, 5 , activation of the complement cascade 43 , activation of the coagulation cascade 43 , activation of an innate-immune-system response in human adipose tissue in obesity and type 2 diabetes 28 , and initiation of obesity 44 .
In mouse models, increased fat mass, body weight and low-grade inflammation in multiple tissues (liver, muscle and adipose tissue) can be induced by a high-fat diet or by subcutaneous lipopolysaccharide infusion 44 . Moreover, mice lacking functional lipopolysaccharide receptors (Cd14 -/-mice) are resistant to the induction of obesity and the metabolic syndrome by high-fat diet or subcutaneous lipopolysaccharide administration 44 . These results are consistent with a known mechanism of activation of the innate immune system by lipopoly saccharide via its interaction with CD14-TLR4-MD-2 complexes 41, 42 . Broad-spectrum antibiotics (ampicillin with neomycin or norfloxacin) reduce endotoxaemia -lipopolysaccharide in the blood -along with inflammation, insulin resistance and fat-mass development in mice that are fed a high-fat diet or that are genetically obese (ob/ob), compared with similar, antibiotic-free mice 45, 46 . Germ-free mice with no intestinal microflora that are fed a high-fat diet do not develop inflammation 47 . One controversial hypothesis suggests that saturated fatty acids promote low-grade inflammation through a TLR4-dependent pathway 48 . Lipopolysaccharide has been shown to interact with the TLR4-CD14 complex to initiate a signalling cascade, which in turn induces the expression of TLR2, further enhancing the innate immune response 49 . These results are consistent with a pathogenic role of lipopolysaccharide originating in the gut in the mediation of the deleterious effects of high-fat feeding. Obesity and gut permeability Obesity has been linked to high intestinal permeability in both animal and human studies 29, 45, 50, 51, 59, 60 . The intestinal mucosa constitutes a selectively permeable barrier between the circulation and intestinal lumen. In a healthy state, the permeability should be well regulated to facilitate the necessary absorption without compromising barrier exclusion. The intercellular tight junctions formed by the interaction between internal membrane proteins and cytoskeletal components regulate intestinal permeability in response to physiological or pathological stimuli, including fatty acids and neurological disorders 62 . Lipopolysaccharide stimulates endocannabinoid synthesis 58, 63 , and the endocannabinoid system has an important role in the regulation of gut permeability. In lean wild-type mice, treatment with a cannabinoid receptor 1 (CB1) agonist increased both gut permeability and plasma lipopolysaccharide levels compared with untreated controls 58 . Conversely, in ob/ ob mice, treatment with a CB1 antagonist reduced plasma lipopoly saccharide levels compared with untreated controls 58 . In an in vitro assay, co-treatment with lipopolysaccharide and a CB1 agonist had a greater effect than lipopolysac charide alone on reduction proinflammatory cytokines (especially IFN-γ and TNF) and are essential to maintain the integrity of the intestinal mucosa 61 . In mice, a high-fat diet contributes to disruption of the expression and localization in the small intestine of the tight junction proteins ZO-1 and occludin 29, 45, 57 .
Endocannabinoids and gut permeability
Compelling evidence has shown that dysregulation of the tight control of endocannabinoid levels in humans can result in elevation of systemic lipopoly saccharide, leading to pathological conditions such as obesity and the metabolic syndrome, or Lipopolysaccharide can activate Toll-like receptors (TLRs) on macrophages in multiple organs including blood vessels, muscles, liver and joints. Complement components interact with TLRs to increase TLR-induced cytokine production through activation of intracellular signalling molecules such as mitogen-activated protein kinases and transcription factors such as nuclear factor κB 91. The complement activation products C3a, C3b and C5a can directly activate macrophages. TLR activation can enhance complement protein biosynthesis and complement receptor expression. Thus, TLR and complement pathways can synergistically activate macrophages. This process can induce insulin resistance, coagulation and atherosclerosis in blood vessels, insulin resistance in muscles, and nonalcoholic fatty-liver disease (NAFLD) and insulin resistance in the liver, which in turn can reduce lipopolysaccharide clearance and increase levels of lipopolysaccharide in the systemic circulation. We propose that in joints this process can exacerbate any underlying osteoarthritis (OA) or pre-OA pathology, such as those initiated by excess mechanical load or injury. High dietary intake of fatty acids can also increase endocannabinoid levels in different tissues, including the intestine 64 , suggesting a mechanism whereby a high-fat diet can increase lipopolysaccharide, thereby triggering the development of obesity and metabolic syndrome.
Intestinal motility
Gut microbiota overgrowth and alteration are associated with reduced intestinal motility, an effect that is potentially mediated by insulin resistance 65 . In a large cohort study 66 , higher lipopolysac charide concentrations an obesity-prone phenotype, a high-fat diet leads to altered gut microbiota, increased luminal lipopolysaccharide, decreased IAP activity and increased tight-junction permeability relative to a low-fat diet 69 . Conversely, increased IAP activity is associated with the reduction of circulating levels of lipopolysaccharide 69 .
Exercise and HDL cholesterol
Systemic endotoxin levels negatively correlate with physical activity, being high in individuals with a sedentary lifestyle and low in those who are highly trained 70 . Clinical studies 71, 72 have shown that aerobic exercise training can increase serum levels of HDL cholesterol from baseline, and HDL cholesterol is negatively correlated with lipopolysaccharide 66 . Notably, clearance of HDL cholesterol by hepatocytes is mediated by control of expression of the scavenger receptor class B member 1 by leptin, and leptin deficiency results in high plasma levels of HDL cholesterol 73, 74 . Leptin deficiency or absence of leptin function in mice prevents the development of OA even in the presence of a high-fat diet and obesity 75 . This effect might be the result of elevation of HDL cholesterol in the absence of leptin protein or function, leading to a high level of lipopolysaccharide clearance. Furthermore, the results of longitudinal studies have shown that physical exercise can reduce not only systemic lipopolysac charide levels, but also TLR4 activation, thereby further reducing the inflammatory response to lipopolysaccharide 76, 77 . The effects of diet and exercise on lipopolysac charide might, at least in part, explain their synergistic benefits for OA 78 .
A potential role in OA Increasingly, evidence suggests that endotoxaemia is intricately associated with several chronic diseases including type 2 diabetes, nonalcoholic steatohepatitis and cardiovascular disease (FIG. 1) . Given the compelling evidence for the association of obesity, the metabolic syndrome, lipopolysaccharide, gut permeability, innate immunity and low-grade inflammation with OA, we hypothesize that lipopolysaccharide in the bloodstream has a role in a two-hit model of OA pathogenesis and potentiation. One factor is the priming of the proinflammatory innate immune response by lipopolysaccharide, the second involves complementary mechanisms, such as joint injury and damage, which synergistically activate innate immunity (FIG. 3) . The rationale underlying this hypothesis is based on several lines of evidence.
were found in patients with diabetes than in individuals without diabetes, and serum levels of lipopolysaccharide-binding protein correlated with indicators of insulin resistance (levels of glycated haemoglobin and results of the homeostatic model assessment-1 algorithm) 67 .
Intestinal alkaline phosphatase
Intestinal alkaline phosphatase (IAP), which has an important role in lipopolysaccharide detoxification through dephosphorylation of the lipid portion of the endotoxin, is implicated in the alteration of gut permeability in zebrafish 68 . In rats with A high-fat diet and insulin resistance associated with obesity can both adversely alter the gut flora (microbiome dysbiosis), leading to a constitutive increase in the delivery of lipopoly saccharide-containing bacterial outer-membrane vesicles to the liver. Insulin resistance also increases gut permeability for outer-membrane vesicles and lipopolysaccharide through alterations to the endo cannabinoid system (upregulation of cannabinoid receptor 1 (CB1)) and downregulation of tight-junction proteins (ZO-1 and occludin) of the gut endothelium. Inadequate clearance of lipopoly saccharide by a fatty liver, owing to low HDL cholesterol production, can lead to the presence of lipopolysaccharide in the systemic circulation. These processes result in a vicious cycle because of the diabetes-promoting and proinflammatory actions of lipopolysaccharide throughout the body. 79 . However, the combination of these two factors synergistically activates macrophages to express high levels of OA-related cytokines 79 . Also, obesity and the metabolic syndrome are associated with insulin resistance and an altered gut microbiome 80 , which could lead to impaired gut permeability, thereby increasing lipopolysaccharide absorption and resulting in the emergence of systemic metabolic endotoxaemia 50 and the induction of low-grade systemic inflammation. With the activation of the innate immune system, the whole process could lead to a pathological vicious cycle.
The functions of lipopolysaccharide can explain aspects of the association between obesity and OA 81, 82 -particularly at non-weight-bearing joints -such as the twofold increased risk of hand OA in obese patients, which cannot be explained by biomechanical factors 83 . Obesity is associated with compromised gut mucosa and elevated serum levels of lipopolysaccharide 50, 51, 59, 60 , providing a mechanism by which inflammation caused by obesity could result in OA. However, many factors potentially contribute to the low-grade inflammation seen in OA, including injuries and genetic factors, such as those regulating the level of the innate immune response, as reviewed previously 84 . Lipopolysaccharide could, therefore, be considered to be neither necessary nor sufficient for OA, but rather an exacerbating factor in a two-hit model of OA. Therapeutic strategies aimed at reducing systemic levels of lipopolysac charide could have benefits for the prevention and treatment of OA. Lipopolysaccharidelowering therapies could include a high-fibre diet, which has been shown to decrease bacterial translocation across the gut in mice 85 . Weight loss is a potential strategy to lower lipopolysaccharide; bariatric surgery can decrease the serum level of lipopolysaccharide-binding protein, an important indicator of lipopoly saccharide in obese patients 86 . Exercise has been shown to cause reductions in systemic lipopolysaccharide concentrations 70 , presumably at least in part as a result of enhancement of lipopolysaccharide clearance through an exercise-mediated increase in HDL cholesterol 71, 72 . Antibiotics can modulate the microbiome in mice 45, 46 , and also in humans, both adversely 87 and beneficially 88 ; an 8-week more widespread, additional pathological mediators are likely to be uncovered. Understanding the relevance of lipopolysaccharide to human arthritides has profound implications for therapy. On the basis of current knowledge, lipopolysaccharide-lowering therapies could include a high-fibre diet, weight loss, exercise, antibiotics and, as a last resort, microbiota transplant 89 . Surveillance of lipopolysac charide levels could catalyse the development of new approaches to diagnosing and treating certain phenotypes of OA. In particular, circulating lipopolysaccharide concentrations could provide a new means of detecting individuals with a more-recalcitrant disease state, who might be at high risk for joint failure and who could be targeted with therapies aimed at lowering lipopolysaccharide levels.
course of the broad-spectrum and virtually unabsorbable antibiotic rifaximin in patients with decompensated liver cirrhosis decreased serum lipopolysaccharide and improved liver function and disease severity, compared with baseline measures 88 . As a last resort, microbiota transplantation could modify the intestinal microbiome 89 . This procedure is now possible in humans, as demonstrated by treatment of Clostridium difficile infection by faecal microbiota transplantation 90 . Although some of these treatments are in the experimental stage, we believe that in the future they could inform new strategies for the prevention and treatment of OA.
Conclusions
Lipopolysaccharide causes both inflammation and obesity, and its clearance is altered through a variety of mechanisms in obesity. Altered clearance of lipopolysaccharide potentially explains how inflammation in obesity results in OA. Lipopolysaccharide could, therefore, be considered a major hidden risk factor for OA. In addition to lipopolysaccharide, bacterial outer-membrane vesicles contain phospholipids, DNA, RNA and proteins 23 , any one of which might also be found to exert subacute toxic or proinflammatory effects that could contribute to chronic disease. As profiling of the constituents of outer-membrane vesicles becomes Figure 3 | Two-hit model of OA pathogenesis involving lipopolysaccharide. The induction of obesity by a high-fat diet could lead to site-specific cartilage strains, which, along with injury, could be triggers for osteoarthritis (OA). Factors contributing to elevation of levels of systemic lipopolysaccharide include a high-fat diet with secondary insulin resistance, Gram-negative bacterial overload in the gastrointestinal tract, and a fatty liver with impairment of lipopolysaccharide clearance. High levels of systemic lipopolysaccharide can activate the innate immune system via macrophage stimulation, which can exacerbate the process of OA triggered by excess cartilage strain. A high level of physical activity can mitigate the effects of lipopolysaccharide, through enhancement of systemic levels of HDL cholesterol and lipopolysaccharide clearance, and through reduction of Toll-like receptor 4 activation to reduce the inflammatory response to lipopolysaccharide. NAFLD, nonalcoholic fatty-liver disease.
